Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...

NEW YORK, Feb 18 (Reuters) - Johnson & Johnson said it has recalled two lots of Simponi injection devices -- one in the United States and one in Europe -- after discovering they may deliver less than ...

The Simponi recall stemmed from a manufacturing problem in Switzerland. As Dow Jones reports, many of the affected lots were set aside before hitting the market, but some 395 of the prefilled ...

REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

For the third time this week, we're reporting on a Johnson & Johnson recall. (See hereand herefor the other two.) This time the recall seems to involve only a few hundred units. As Dow Jones Newswires ...

Simponi works by blocking tumor necrosis factor (TNF), which plays an important role in causing abnormal inflammatory and immune responses. Previously approved to treat rheumatoid arthritis, psoriatic ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

The US Food and Drug Administration (FDA) today approved a new indication for the tumor necrosis factor (TNF)-alpha inhibitor golimumab (Simponi, Janssen Biotech): treatment of adults with moderate to ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis. Simponi works by blocking tumor necrosis ...